Compare Dow Inc (DOW) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Natera Inc. Common Stock — how do they compare? Dow Inc trades at $29.35 (market cap $20.59B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.8× Dow Inc's market cap, and Dow Inc pays a 4.91% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 83 Days and Natera Inc. Common Stock for 0 Days on average.
| DOW | NTRA | |
|---|---|---|
Market Cap | $20.59B | $57.03B |
Volume | 5,540,746 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $425.64 |
52-Week Low | $20.95 | $179.42 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $36.29B | $56.18B |
Dividend Yield | 4.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $29.19, up 3.81% on the day, with a bearish technical signal and neutral oscillators. The company reported negative net income of -$2.62B in 2025, with declining revenue from $56.9B in 2022 to $40.0B in 2025. Recent earnings have beaten expectations, but profitability metrics like ROE (-7.86%) and net margin (-3.13%) remain weak. Analyst consensus is a $33.80 price target with mixed ratings (30.56% Buy, 55.56% Hold).
The outlook is cautious due to persistent margin pressures and high debt levels, though the dividend payout and earnings beats offer some stability. Risks include cyclical demand weakness and rising leverage, but the stock trades below consensus target, suggesting potential upside if operational improvements materialize.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
